griseofulvin (grisactin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Once the keratin-Griseofulvin complex reaches the skin site of action, it binds to fungal microtubules (tubulin) thus altering fungal mitosis. Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to and interferes with the function of spindle and cytoplasmic microtubules by binding to alpha and beta tubulin. It binds to keratin in human cells, then once it reaches the fungal site of action, it binds to fungal microtubes thus altering the fungal process of mitosis.   NCATS

Chemistry

  • SMILES: COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC
  • InChIKey: DDUHZTYCFQRHIY-RBHXEPJQSA-N
  • Mol. Mass: 352.766
  • ALogP: 2.81
  • ChEMBL Molecule:
    griseofulvin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.1064 - $0.4026

United States

$1.3190 - $8.0033
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

amudane | curling factor | fulcin | fulcin 125 | fulcin 500 | fulsovin | fulvicin | fulvicin p/g | fulvicin-p/g | fulvicin p/g 165 | fulvicin p/g 330 | fulvicin-u/f | grifulvin | grifulvin v | grisactin | grisactin ultra | grisefulin | griseofulvin | (+)-griseofulvin | griseofulvina | griseofulvine | griseofulvin, microcrystalline | griseofulvin, microsize | griseofulvin, ultramicrocrystalline | griseofulvin,ultramicrosize | griseofulvin, ultramicrosize | griseofulvinum | grisol af | grisovin | gris-peg | grivate | grysio | lamoryl | likuden | poncyl | spirofulvin | sporostatin | ultragris-165 | ultragris-330

Organizations (19)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (6)


 

Candidiasis

Infections

Mycoses (approved 1975)

Tinea

Tinea Capitis

Tinea Pedis

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Antifungal Agents (Phase 1)

Diabetes Mellitus (Phase 1)

Healthy Volunteers (Phase 1)

Tinea Capitis (Phase 3)

Tinea Pedis ()

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue